

DAFTAR PUSTAKA

- AbdelBaki MS, Boué DR, Finlay JL, Kieran MW. 2018. Desmoplastic nodular medulloblastoma in young children: a management dilemma. *Neuro Oncol.* Jul 5;20(8):1026-1033. doi: 10.1093/neuonc/nox222.
- Amayiri N, Swaidan M, Ibrahim A, Hirnas N, Musharbash A, Bouffet E, Al-Hussaini M, Ramaswamy V. 2021. Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country. *JCO global oncology*, 7, 1442–1453. doi: 10.1200/GO.21.00127
- Ashley DM, Merchant TE, Strother D, Zhou T, Duffner P, Burger PC, dkk. 2012. Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. *J Clin Oncol.* Sep 10;30(26):3181-6. doi: 10.1200/JCO.2010.34.4341.
- Batora NV, Sturm D, Jones DT, Kool M, Pfister SM, Northcott PA. 2014. Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics. *Neuroscience.* Apr 4;264:171-85. doi: 10.1016/j.neuroscience.2013.07.030.
- Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, dkk. 2005. Profile of daily life in children with brain tumors: an assessment of health-related quality of life. *J Clin Oncol.* Aug 20;23(24):5493-500. doi: 10.1200/JCO.2005.10.190.
- Bianchi C, Giammusso V, Berti N, Vassallo A. 1979. Medulloblastoma in a patient with xeroderma pigmentosum. *Pathologica.* Sep-Oct;71(1015):697-701. Italian. PMID: 551389.
- Bleil CB, Bizzi JWJ, Bedin A, de Oliveira FH, Antunes ACM. 2019. Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016. *Surg Neurol Int.* Jun 25;10:120. doi: 10.25259/SNI-237-2019.
- Bokun J, Grujicic D, Skender-Gazibara M, Paripovic L, Pekmezovic T, Kistic-Tepavcevic D, dkk. 2018. Management and treatment of children with medulloblastoma in Serbia, a middle-income country. *Journal of B.U.ON.: official journal of the Balkan Union of Oncology*, 23(4), 1156–1162. PMID: 30358225
- Bouzidi Y, Barteau E, Lejeune J, Dejobert M, Gravelier B, Sirinelli D, dkk. 2019. Detection of recurrent brain tumors in children: No significant difference in sensitivity between unenhanced and contrast-enhanced MRI. *Neuroradiol J.* Aug;32(4):259-266. doi: 10.1177/1971400919845619.

- Brugières L, Remenieras A, Pierron G, Varlet P, Forget S, Byrde V, dkk. 2012. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. *J Clin Oncol*. Jun 10;30(17):2087-93. doi: 10.1200/JCO.2011.38.7258.
- Caron HN, Biondi A, Boterberg T, Doz F. 2021. Embryonal Central Nervous System Tumors. Dalam: *Oxford Textbook of Cancer in Children* 7th ed. Oxford University Press. h.188-97.
- Carta R, Del Baldo G, Miele E, Po A, Besharat ZM, Nazio F, dkk. 2020. Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era. *Front Oncol*. Oct 29;10:566822. doi: 10.3389/fonc.2020.566822.
- Chi SN, Gardner SL, Levy AS, Knopp EA, Miller DC, Wisoff JH, dkk. 2005. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. *J Clin Oncol*. Apr 20;23(12):2877. doi: 10.1200/JCO.2004.12.126
- Chiang JC, Ellison DW. 2017. Molecular pathology of paediatric central nervous system tumours. *J Pathol*. Jan;241(2):159-172. doi: 10.1002/path.4813.
- Clark TG, Bradburn MJ, Love SB, Altman DG. 2003. Survival analysis part I: basic concepts and first analyses. *Br J Cancer*. Jul 21;89(2):h.232-8. doi: 10.1038/sj.bjc.6601118.
- Cohen BH, Geyer JR, Miller DC, Curran JG, Zhou T, Holmes E, dkk. 2015. Children's Oncology Group. Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. *Pediatr Neurol*. Jul;53(1):31-46. doi: 10.1016/j.pediatrneurol.2015.03.019.
- Cohen SB. 1982. Familial polyposis coli and its extracolonic manifestations. *J Med Genet*. Jun;19(3):193-203. doi: 10.1136/jmg.19.3.193.
- de Chadarevian JP, Vekemans M, Bernstein M. 1985. Fanconi's anemia, medulloblastoma, Wilms' tumor, horseshoe kidney, and gonadal dysgenesis. *Arch Pathol Lab Med*. Apr;109(4):367-9. PMID: 2985019.
- Deutsch M, Thomas PR, Krischer J, Boyett JM, Albright L, Aronin P, dkk. 1996. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. *Pediatr Neurosurg*. 24(4):167-176; discussion 176-7. doi: 10.1159/000121042.

- Dewi SP, Gondhowiardjo SA, Mangunatmadja I, Aman RA, Kodrat H, Permata TBM, Handoko. 2022. Quality of life in children with brain tumors post radiotherapy in a lower-middle income country, *Pediatric Hematology and Oncology*, doi: 10.1080/08880018.2022.2144559
- Dhall G. 2020. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial. *Neuro Oncol.* Dec 18;22(12):1862-1872. doi: 10.1093/neuonc/noaa102.
- Diaz-Coronado RY, Reinecke JB, Stanek JR, Finlay JL, Hernández Broncano E, Chávez Paredes S, dkk. 2022. Factors influencing outcomes of older children with medulloblastoma over 15 years in Peru, a resource-limited setting. *Pediatric blood & cancer*, 69(10), e29770. doi: 10.1002/pbc.29770
- Distel L, Neubauer S, Varon R, Holter W, Grabenbauer G. 2003. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. *Med Pediatr Oncol.* Jul;41(1):44-8. doi: 10.1002/mpo.10275
- Eid AM, Heabah NAEG. 2021. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups. *J Egypt Natl Canc Inst* 33, 6. doi: 10.1186/s43046-021-00060-w
- Erez A, Ilan T, Amariglio N, Muler I, Brok-Simoni F, Rechavi G, dkk. 2002. GLI3 is not mutated commonly in sporadic medulloblastomas. *Cancer.* Jul 1;95(1):28-31. doi: 10.1002/cncr.10642.
- Estellés LI, Charriel PB, Nieto AC. 2017. Medulloblastoma: improved survival in recent decades. Unicentric experience. *An Pediatr (Barc).* Jan;86(1):4-10. doi: 10.1016/j.anpedi.2016.03.004.
- Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, dkk. 1990. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. *J Neurosurg.* Apr;72(4):572-82. doi: 10.3171/jns.1990.72.4.0572.
- Evans G, Burnell L, Campbell R, Gattamaneni HR, Birch J. 1993. Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. *Med Pediatr Oncol.* 21(6):433-4. doi: 10.1002/mpo.2950210608.
- Fahmideh MA, Scheurer ME. 2021. Pediatric Brain Tumors: Descriptive Epidemiology, Risk Factors, and Future Directions. *Cancer Epidemiology, Biomarkers & Prevention*, 30, 813-21. doi: 10.1158/1055-9965.EPI-20-1443

- Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, dkk. 2006. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. *Lancet Oncol.* Oct;7(10):813-20. doi: 10.1016/S1470-2045(06)70867-1.
- Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, dkk. 2021. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). *J Clin Oncol.* Mar 1;39(7):822-835. doi: 10.1200/JCO.20.01372.
- Giovannetti E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, de Lange D, dkk. 2008. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSEr) polymorphisms in Indonesian children with and without leukemia. *Leuk Res.* Jan;32(1):19-24. doi: 10.1016/j.leukres.2007.02.011.
- Girardi F, Allemani C, Coleman MP. 2019. Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review. *J Global Oncol.* doi 10.1200/JGO.19.00140.
- Gittleman HR. 2014. Trends in Central Nervous System Tumor Incidence Relative to Other Common Cancers in Adults, Adolescents, and Children in the United States, 2000 to 2010. *Wiley Online Library.* h.102-112. doi: 10.1002/cncr.2901.
- Grill J, Sainte-Rose C, Jouvett A, Gentet JC, Lejars O, Frappaz D, dkk. 2005. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. *Lancet Oncol.* 2005 Aug;6(8):573-80. doi: 10.1016/S1470-2045(05)70252-7.
- Gupta N, Banerjee A, Haas-Kogan D. 2016. Chapter 5: embryonal tumors. Dalam: *Pediatric CNS Tumors.* Springer. h.93–104.
- Hanson D, Atlas MP. 2022. Central Nervous System Tumors. Dalam: *Lanzkowsky's Manual of Pediatric Hematology and Oncology* 7th ed. Elsevier Inc. h.485-504.
- Hart RM, Kimler BF, Evans RG, Park CH. 1987. Radiotherapeutic management of medulloblastoma in a pediatric patient with ataxia telangiectasia. *Int J Radiat Oncol Biol Phys.* Aug;13(8):1237-40. doi: 10.1016/0360-3016(87)90200-8.
- Herdell V, Lassarén P, Boop FA, Bartek J Jr, Uche EO, Tisell M. 2022. Surgical outcomes of pediatric brain tumors in Sub-Saharan Africa: A systematic review. *Brain Spine.* Jul 3;2:100912. doi: 10.1016/j.bas.2022.100912.

- Hossain J, Xiao W, Tayeb M, Khan S. 2021. Epidemiology and prognostic factors of pediatric brain tumor survival in the US: Evidence from four decades of population data. *Cancer Epidemiol.* June; 72: 101942. doi: 10.1016/j.canep.2021.101942.
- Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. 2020. Medulloblastomics revisited: biological and clinical insights from thousands of patients. *Nat Rev Cancer.* 20(1): h.42–56.
- Hoyle R. 2018. Chapter 7. Analysis Techniques for Small Population Research. Dalam Nancy Kirkendall and Jordyn White (Rapporteurs). *Improving Health Research on Small Populations. Proceedings of A Workshop.* The National Academies Press.
- Huang A, Lindsay HL, Tamrazi B, Adesina AM, Paulino AC, Pollack IF, dkk. 2021. Tumor of the Central Nervous System: Embryonal and Pineal Region Tumors. dalam Blaney SM, Adamson PC, Helman LJ. *Pediatric Oncology* 8th ed. Wolters Kluwer. h.1858-90.
- Huang PI, Lin SC, Lee YY, Ho DM, Guo WY, Chang KP, dkk. 2017. Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute. *Childs Nerv Syst.* Aug;33(8):1285-1294. doi: 10.1007/s00381-017-3435-9.
- Jaafari M, Razine R, Haroun AE, Tahiri Z, Hessissen L. 2023. Childhood Medulloblastoma in Morocco (middle-income country): Therapeutic outcomes and survival. *Ther Radiol Oncol,* 09(5):1-11. doi: 10.21037/tro-22-39
- Johnston DL, Keene D, Kostova M, Strother D, Lafay-Cousin L, Fryer C, dkk. 2014. Incidence Of Medulloblastoma in Canadian Children. *J Neurooncol.* Dec;120(3):575-9. doi: 10.1007/s11060-014-1588-x.
- Johnston DL, Keene D, Strother D, Taneva M, Lafay-Cousin L, Fryer C, dkk. 2018. Survival Following Tumor Recurrence in Children With Medulloblastoma. *J Pediatr Hematol Oncol.* Apr; 40(3):e159-e163. doi: 10.1097/MPH.0000000000001095.
- Jones DT, Northcott PA, Kool M, Pfister SM. 2013. The role of chromatin remodeling in medulloblastoma. *Brain Pathol.* Mar;23(2). h.193-9. doi: 10.1111/bpa.12019.
- Kaatsch P, Grabow D, Spix C. 2016. German Childhood Cancer Registry — Annual Report. *Kinderkrebsregister.* Didapat dari <http://www.kinderkrebsregister.de/dkkkr-gb/latest-publications/annual-reports/annual-report-2016.html>

- Kementerian Kesehatan Republik Indonesia. 2020. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tumor Otak. Jakarta, Indonesia.
- Khanna V, Achey RL, Ostrom QT, Block-Beach H, Kruchko C, Barnholtz-Sloan JS, dkk. 2017. Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. *J Neurooncol.* Dec;135(3):433-441. doi: 10.1007/s11060-017-2594-6.
- Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, dkk. 2012. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. *Acta Neuropathol.* Apr;123(4):473-84. doi: 10.1007/s00401-012-0958-8.
- Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, dkk. 2014. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell.* Mar 17;25(3):393-405. doi: 10.1016/j.ccr.2014.02.004.
- Korshunov A, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt H, dkk. 2010. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. *Acta Neuropathol.* Aug;120(2):253-60. doi: 10.1007/s00401-010-0688-8.
- Korshunov A, Ryzhova M, Jones DT, Northcott PA, van Sluis P, Volckmann R, dkk. 2012. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). *Acta Neuropathol.* Dec;124(6):875-81. doi: 10.1007/s00401-012-1068-3.
- Lafay-Cousin L, Bouffet E, Strother D, Rudneva V, Hawkins C, Eberhart C, dkk. 2020. Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). *J Clin Oncol.* Jan 20;38(3):h.223-31. doi: 10.1200/JCO.19.00845.
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, dkk. 2021. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* Aug 2;23(8):h.1231-51. doi: 10.1093/neuonc/noab106.
- Massimino M, Biassoni V, Gandola L, Garrè ML, Gatta G, Giangaspero F, dkk. 2016. Childhood medulloblastoma. *Critical Reviews in Oncology/Hematology*, Volume 105, h.35-51, <https://doi.org/10.1016/j.critrevonc.2016.05.012>.

- Mehrvar A, Tashvighi M, Hedayati Asl AA, Niktoreh-Mofrad N, Mehrvar N, Afsar N, dkk. 2018. Management and outcomes of treating pediatric medulloblastoma: an eight years' experience in an Iranian pediatric center. *Childs Nerv Syst* 34, 639–647. doi: 10.1007/s00381-017-3672-y
- Moss RM, Sorajja N, Mills LJ, Moertel CL, Hoang TT, Spector LG, dkk. 2023. Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors. *Frontiers in oncology*, 13, 1113121. <https://doi.org/10.3389/fonc.2023.1113121>
- Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, dkk. 2020. Nonmetastatic medulloblastoma of early childhood: results from the prospective clinical trial HIT-2000 and an extended validation cohort. *J Clin Oncol*. Jun 20;38(18):2028-2040. doi: 10.1200/JCO.19.03057.
- Nalita N, Ratanalert S, Kanjanapradit K, Chotsampancharoen T, Tunthanathip T. 2018. Survival and Prognostic Factors in Pediatric Patients with Medulloblastoma in Southern Thailand. *J Pediatr Neurosci*. Apr-Jun;13(2):150-157. doi: 10.4103/jpn.JPN_111_17.
- Narayan V, Sugur H, Jaiswal J, Arvinda HR, Arivazhagan A, Somanna S, dkk. 2019. Medulloblastoma: Distinctive Histo-Molecular Correlation with Clinical Profile, Radiologic Characteristics, and Surgical Outcome. *Pediatr Neurosurg*. 54(5):329-340. doi: 10.1159/000501913.
- Northcott PA, Jones D, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, dkk. 2012. Medulloblastomics: the end of the beginning. *Nat Rev Cancer* 12, h.818–34. doi: 10.1038/nrc3410.
- Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, dkk. 2009. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. *Nat Genet*. Apr;41(4):h.465-72. doi: 10.1038/ng.336.
- Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, dkk. 2019. Medulloblastoma. *Nat Rev Dis Primers*. Feb 14;5(1):h.11. doi: 10.1038/s41572-019-0063-6.
- Oigman G, Osorio DS, Ferman S, Stanek JR, Aversa do Souto, dkk. 2022. Epidemiological characteristics and survival outcomes of children with medulloblastoma treated at the National Cancer Institute (INCA) in Rio de Janeiro, Brazil. *Pediatric blood & cancer*, 69(1), e29274. doi: 10.1002/pbc.29274
- Ostrom QT, Fahmideh MA, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, dkk. 2019. Risk factors for childhood and adult primary brain tumors. *Neuro Oncol*. Nov 4;21(11):h.1357-75. doi: 10.1093/neuonc/noz123.

- Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. 2018. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. *Neuro Oncol.* Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131.
- Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, dkk. 2006. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. *J Clin Oncol.* Sep 1;24(25):h.4202-8. doi: 10.1200/JCO.2006.06.4980.
- Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, dkk. 1994. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. *J Neurosurg.* Nov;81(5):h.690-8. doi: 10.3171/jns.1994.81.5.0690.
- Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, dkk. 1991. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. *J Neurosurg.* Mar;74(3):h.433-40. doi: 10.3171/jns.1991.74.3.0433.
- Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. 2013. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. *Neuro Oncol.* Jan;15(1):h.97-103. doi: 10.1093/neuonc/nos267.
- Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, dkk. 2017. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. *Acta Neuropathol.* Nov;134(5):h.705-14. doi: 10.1007/s00401-017-1752-4.
- Parkes J, Hendricks, M., Ssenyonga, P., Mugamba, J., Molyneux, E., Schouten-van Meeteren, A, dkk. 2015, SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. *Pediatr Blood Cancer*, 62: h.553-64. doi: 10.1002/pbc.25313
- Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, dkk. 2011. The genetic landscape of the childhood cancer medulloblastoma. *Science.* Jan 28;331(6016):h.435-9. doi: 10.1126/science.1198056.
- Parsons DW, Pollack IF, Hass-Kogan DA, Paulino AC, Kralik SF., Desai NK, dkk. 2021. Gliomas, ependymomas, and other nonembryonal tumors of the central nervous system. Dalam: Blaney SM, Adamson PC, Helman LJ. *Principles and practice of pediatric oncology*, 8th ed, Pizzo P, Poplack D (Eds), Lippincott Williams & Wilkins, Philadelphia. h.1761-846.

- Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D, dkk. 2014. MRI surrogates for molecular subgroups of medulloblastoma. *AJNR Am J Neuroradiol*. Jul;35(7):h.1263-9. doi: 10.3174/ajnr.A3990.
- Petrella R, Hirschhorn K, German J. 1991. Triple autosomal trisomy in a pregnancy at risk for Bloom's syndrome. *Am J Med Genet*. Sep 1;40(3):h.316-8. doi: 10.1002/ajmg.1320400314.
- Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, dkk. 2016. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. *Acta Neuropathol*. Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6.
- Riedemann J, Figaji AA, Davidson A, Stannard C, Pillay K, Kilborn T, dkk. 2021. Sequential improvement in paediatric medulloblastoma outcomes in a low-and-middle-income country setting over three decades. *SA Journal of Oncology*, 1462(5):1. doi:10.4102/sajo.v5i0.174
- Robinson GW, Gajjar A. 2020. Genomics paves the way for better infant medulloblastoma therapy. *J Clin Oncol*. 38(18):h.2010-3. doi: 10.1200/JCO.20.00593
- Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, dkk. 2018. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. *Lancet Oncol*. Jun;19(6): h.768-84. doi: 10.1016/S1470-2045(18)30204-3.
- Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, dkk. 2005. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. *N Engl J Med*. Mar 10;352(10):978-86. doi: 10.1056/NEJMoa042176.
- Sastroasmoro S dan Ismael S. 2014. *Dasar-dasar Metodologi Penelitian Klinis* edisi ke-5. Sagung Seto.
- Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, dkk. 2017. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. *Lancet Oncol*. Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7.
- Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, dkk. 2014. Cytogenetic prognostication within medulloblastoma subgroups. *J Clin Oncol*. Mar 20;32(9):h.886-96. doi: 10.1200/JCO.2013.50.9539.

- Smith MJ, Beetz C, Williams SG, Bhaskar SS, O'Sullivan J, Anderson B, dkk. 2014. Germline mutations in *SUFU* cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with *PTCH1* mutations. *J Clin Oncol*. Dec 20;32(36):h.4155-61. doi: 10.1200/JCO.2014.58.2569.
- Taeubner J, Wimmer K, Muleris M, Lascols O, Colas C, Fauth C, dkk. 2018. Diagnostic challenges in a child with early onset desmoplastic medulloblastoma and homozygous variants in *MSH2* and *MSH6*. *Eur J Hum Genet*. Mar;26(3):h.440-4. doi: 10.1038/s41431-017-0071-5.
- Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. 1990. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). *Eur J Cancer*. Apr;26(4):464-9. PMID: 2141512.
- Tarbell NJ, Friedman H, Polkinghorn WR, Yock T, Zhou T, Chen Z, dkk. 2013. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). *J Clin Oncol*. Aug 10;31(23):h.2936-41. doi: 10.1200/JCO.2012.43.9984.
- Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, dkk. 2002. Mutations in *SUFU* predispose to medulloblastoma. *Nat Genet*. Jul;31(3):h.306-10. doi: 10.1038/ng916.
- Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, dkk. 2012. Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathol*. 123(4): h.465–72. doi: 10.1007/s00401-011-0922-z
- Thewes B, Rietjens JAC, van den Berg SW, Compen FR, Abrahams H, Poort H, dkk. 2018. One way or another: The opportunities and pitfalls of self-referral and consecutive sampling as recruitment strategies for psycho-oncology intervention trials. *Psychooncology*. Aug;27(8):2056-2059. doi: 10.1002/pon.4780.
- Tommerup N, Nielsen F. 1983. A familial reciprocal translocation *t*(3;7) (p21.1;p13) associated with the Greig polysyndactyly-craniofacial anomalies syndrome. *Am J Med Genet*. Nov;16(3):h.313-21. doi: 10.1002/ajmg.1320160304.
- Twigg SRF, Hufnagel RB, Miller KA, Zhou Y, McGowan SJ, Taylor J, dkk. 2016. A Recurrent Mosaic Mutation in *SMO*, Encoding the Hedgehog Signal Transducer Smoothed, Is the Major Cause of Curry-Jones Syndrome. *Am J Hum Genet*. Jun 2;98(6):h.1256-65. doi: 10.1016/j.ajhg.2016.04.007.

- von Bueren AO, von Hoff K, Pietsch T, Gerber NU, Warmuth-Metz M, Deinlein F, dkk. 2011. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. *Neuro Oncol.* Jun;13(6):h.669-79. doi: 10.1093/neuonc/nor025.
- von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T, dkk. 2010. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. *Pediatr Blood Cancer.* Mar;54(3):369-76. doi: 10.1002/pbc.22339.
- Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, dkk. 2018. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. *Neuro Oncol.* Jan 10;20(1):13-23. doi: 10.1093/neuonc/nox087.
- Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, dkk. 2018. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncol.* Jun;19(6):h.785-98. doi: 10.1016/S1470-2045(18)30242-0.
- Yeom KW, Mobley BC, Lober RM, Andre JB, Partap S, Vogel H, dkk. 2013. Distinctive MRI features of pediatric medulloblastoma subtypes. *AJR Am. J. Roentgenol.* 200 (4), h.895–903.
- Yock TI, Bhat S, Szymonifka J, Yeap BY, Delahaye J, Donaldson SS, dkk. 2014. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. *Radiotherapy and Oncology*, Volume 113, Issue 1, h.89-94. doi: 10.1016/j.radonc.2014.08.017